ENTRY       D06404                      Drug
NAME        Liraglutide (USAN/INN);
            Liraglutide (genetical recombination) (JAN);
            Victoza (TN)
PRODUCT     SAXENDA (A-S Medication Solutions)
            SAXENDA (Novo Nordisk Pharmaceutical Industries)
            VICTOZA (A-S Medication Solutions)
            VICTOZA (A-S Medication Solutions)
            VICTOZA (Novo Nordisk)
  GENERIC   LIRAGLUTIDE (A-S Medication Solutions)
            LIRAGLUTIDE (A-S Medication Solutions)
            LIRAGLUTIDE (Biocon Pharma)
            LIRAGLUTIDE (Biocon Pharma)
            LIRAGLUTIDE (Cipla USA)
            LIRAGLUTIDE (Cipla USA)
            LIRAGLUTIDE (Hikma Pharmaceuticals USA)
            LIRAGLUTIDE (Hybio Pharmaceutical)
            LIRAGLUTIDE (Hybio Pharmaceutical)
            LIRAGLUTIDE (Hybio Pharmaceutical)
            LIRAGLUTIDE (Lupin Pharmaceuticals)
            LIRAGLUTIDE (Meitheal Pharmaceuticals)
            LIRAGLUTIDE (NorthStar Rx LLC)
            LIRAGLUTIDE (Orbicular Pharmaceutical Technologies Private Limited)
            LIRAGLUTIDE (Orbicular Pharmaceutical Technologies Private Limited)
            LIRAGLUTIDE (Teva Pharmaceuticals USA)
            LIRAGLUTIDE (Teva Pharmaceuticals)
FORMULA     C172H265N43O51
EXACT_MASS  3748.9465
MOL_WEIGHT  3751.20
SEQUENCE    His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
            Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly
            (-Glu combined: 20)
  TYPE      Peptide
CLASS       Antidiabetic agent
             DG02044  Hypoglycemic agent
              DG01493  GLP-1 receptor agonist
REMARK      Therapeutic category: 2499
            ATC code: A10BJ02
            Product: D06404<JP/US>
            Product (mixture): D11567<JP/US>
EFFICACY    Antidiabetic, Glucagon-like peptide 1 (GLP-1) receptor agonist
  DISEASE   Type 2 diabetes mellitus [DS:H00409]
  TYPE      Modified peptide
COMMENT     Human glucagon-like peptide 1 (GLP-1) [CPD:C16048] analog
            Adjunctive thrapy to improve glycemic control, with diet and exercise in patients with type II diabetes
TARGET      GLP1R [HSA:2740] [KO:K04581]
  PATHWAY   hsa04080(2740)  Neuroactive ligand-receptor interaction
            hsa04911(2740)  Insulin secretion
INTERACTION  
STR_MAP     map07051  Antidiabetics
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A10 DRUGS USED IN DIABETES
               A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
                A10BJ Glucagon-like peptide-1 (GLP-1) analogues
                 A10BJ02 Liraglutide
                  D06404  Liraglutide (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Anti-Obesity Agents
              Liraglutide
               D06404  Liraglutide (USAN/INN)
             Blood Glucose Regulators
              Antidiabetic Agents
               GLP-1 Receptor Agonist
                Liraglutide
                 D06404  Liraglutide (USAN/INN)
             Kidney Agents
              GLP-1 Receptor Agonist
               Liraglutide
                D06404  Liraglutide (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              24  Hormones
               249  Miscellaneous
                2499  Others
                 D06404  Liraglutide (USAN/INN); Liraglutide (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Antidiabetic agent
              DG02044  Hypoglycemic agent
               DG01493  GLP-1 receptor agonist
                D06404  Liraglutide
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Secretin receptor family
               Glucagon
                GLP1R
                 D06404  Liraglutide (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D06404
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D06404
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D06404
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D06404
DBLINKS     CAS: 204656-20-2
            PubChem: 47208061
            ChEBI: 71193
            J-GLOBAL: J2.404.888H
///